| answer text |
<p>We are aware of disruptions to the supply of medicines used for the management
of attention deficit hyperactivity disorder (ADHD). While some issues have now been
resolved, we know that there are currently disruptions to the supply of some other
medicines, primarily driven by issues which have resulted in capacity constraints
at key manufacturing sites. These issues are expected to resolve in early 2024.</p><p>
</p><p>We understand how frustrating and distressing medicine shortages can be and
we want to assure patients that we are working intensively with the respective manufacturers
to resolve the issues as soon as possible and to ensure patients have continuous access
to ADHD medicines in the United Kingdom, in the short and long term.</p><p> </p><p>We
have issued communications to the National Health Service to advise healthcare professionals
on management of patients whilst there continue to be disruptions to supplies. Patients
are advised to speak to their clinician regarding any concerns they have and to discuss
the suitability of treatment with alternative medicines.</p>
|
|
